CalciMedica Inc Ordinary Shares CALC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
CalciMedica to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
CalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
CalciMedica Announces One-for-Five Reverse Stock Split
CalciMedica Reports Second Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
CalciMedica Shares Hit 52-Week Low After Ending Auxora Trial
Trading Information
- Previous Close Price
- $1.35
- Day Range
- $1.24–1.31
- 52-Week Range
- $1.04–35.40
- Bid/Ask
- $0.00 / $0.00
- Shares Outstanding
- 6.83M
- Market Cap
- $8.88M
- Volume/Avg
- 24,296 / 81,649
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 15
- Website
- https://www.calcimedica.com
Valuation
Metric | CALC |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.43 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
CALC
Financial Strength
Metric | CALC |
|---|---|
Quick Ratio | 5.33 |
Current Ratio | 5.58 |
Interest Coverage | −15.75 |
Quick Ratio
CALC
Profitability
Metric | CALC |
|---|---|
Return on Assets (Normalized) | −116.20% |
Return on Equity (Normalized) | −2,441.30% |
Return on Invested Capital (Normalized) | −179.69% |
Return on Assets
CALC
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|Cff$x# | LOCK|v^!R? | $138B | |||
| Moderna Inc MRNA | LOCK|>&rHnTV | LOCK|Lz | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|^<SCY?Y | LOCK|N@Vd | $93B | |||
| argenx SE ADR ARGX | LOCK|r?RJqP | LOCK|gR | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|%r#C^p | LOCK|># | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|^%PH>YL | LOCK|Td^$m | $30B | |||
| Incyte Corp INCY | LOCK|D#xDWt | LOCK|#n^ | $24B | |||
| BioNTech SE ADR BNTX | LOCK|&YBc!c | LOCK|#s | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|jgQw#n | LOCK|k^B%k | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|B?G<Y? | LOCK|?TN | $15B |
United States